Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.
J Clin Psychiatry
; 70(1): 46-57, 2009 Jan.
Article
en En
| MEDLINE
| ID: mdl-19026248
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and tolerability of low daily doses of controlled-release (CR) paroxetine in patients with late-life depression.METHOD:
This was a 10-week, multicenter, placebo-controlled, double-blind, fixed-dose trial randomly assigning patients >or= 60 years old to daily doses of paroxetine CR 12.5 mg (N = 168), paroxetine CR 25 mg (N = 177), or placebo (N = 180). Patients had major depressive disorder (DSM-IV criteria) and 17-item Hamilton Rating Scale for Depression (HAM-D) total scores of >or= 18. The primary efficacy variable was the change from baseline to study endpoint in total HAM-D scores. The study was conducted from June 2003 to October 2004.RESULTS:
The drug/placebo difference in HAM-D change from baseline at study endpoint was -1.8 (95% CI = -3.41 to -0.19, p = .029) for paroxetine CR 12.5 mg, and -3.3 (95% CI = -4.84 to -1.68, p < .001) for paroxetine CR 25 mg. A significantly larger percentage of patients achieved remission (HAM-D total scoreCONCLUSION:
These data demonstrate that paroxetine CR 12.5 mg and 25 mg daily are efficacious and well tolerated in the treatment of major depressive disorder in patients >or= 60 years of age, although effect sizes are relatively smaller with the 12.5 mg/day dose.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Paroxetina
/
Antidepresivos de Segunda Generación
/
Trastorno Depresivo Mayor
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Idioma:
En
Revista:
J Clin Psychiatry
Año:
2009
Tipo del documento:
Article